Anavex Life Sciences Corp. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
Q2 2024 | 2 | -$0.16 | -$0.16 | -$0.16 |
Q3 2024 | 1 | -$0.16 | -$0.16 | -$0.16 |
Q1 2025 | 1 | -$0.16 | -$0.16 | -$0.16 |
Q2 2025 | 1 | -$0.18 | -$0.18 | -$0.18 |
Q3 2025 | 1 | -$0.17 | -$0.17 | -$0.17 |
Q4 2025 | 1 | $1.53 | $1.53 | $1.53 |
Q1 2026 | 1 | $1.52 | $1.52 | $1.52 |
Q2 2026 | 1 | $1.49 | $1.49 | $1.49 |
Q3 2026 | 1 | $1.46 | $1.46 | $1.46 |
Q4 2026 | 1 | $2.12 | $2.12 | $2.12 |
Q1 2027 | 1 | $2.15 | $2.15 | $2.15 |
Q2 2027 | 1 | $2.17 | $2.17 | $2.17 |
Q3 2027 | 1 | $2.27 | $2.27 | $2.27 |
Q4 2027 | 1 | $3.05 | $3.05 | $3.05 |
Q1 2028 | 1 | $3.09 | $3.09 | $3.09 |
Q2 2028 | 1 | $3.11 | $3.11 | $3.11 |
Q3 2028 | 1 | $3.26 | $3.26 | $3.26 |
Anavex Life Sciences Corp. Earnings Date And Information
Anavex Life Sciences Corp. last posted its earnings results on Tuesday, August 6th, 2024. The company reported $-0.14 earnings per share for the quarter, topping analysts' consensus estimates of $-0.15 by $0.01. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Anavex Life Sciences Corp. has generated $-1 earnings per share over the last year ($-0.6 diluted earnings per share) and currently has a price-to-earnings ratio of -16.35. Anavex Life Sciences Corp. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 24th, 2024 based on prior year's report dates.
Anavex Life Sciences Corp. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/06/2024 | Q3 2024 | -$0.15 | -$0.14 | 0.01 | $0 | $0 |
05/09/2024 | Q2 2024 | -$0.13 | -$0.13 | 0 | $0 | |
02/07/2024 | Q1 2024 | -$0.15 | -$0.11 | 0.04 | $0 | |
11/27/2023 | Q4 2023 | -$0.16 | -$0.13 | 0.03 | $0 | |
08/08/2023 | Q3 2023 | -$0.17 | -$0.14 | 0.03 | $0 | |
05/09/2023 | Q2 2023 | -$0.18 | -$0.17 | 0.01 | $0 | |
02/07/2023 | Q1 2023 | -$0.20 | -$0.17 | 0.03 | $0 | |
11/28/2022 | Q4 2022 | -$0.16 | -$0.19 | -0.03 | $0 | |
08/09/2022 | Q3 2022 | -$0.15 | -$0.16 | -0.01 | $0 | |
05/10/2022 | Q2 2022 | -$0.16 | -$0.14 | 0.02 | $0 | |
02/09/2022 | Q1 2022 | -$0.16 | -$0.14 | 0.02 | $0 | |
11/24/2021 | Q4 2021 | -$0.13 | -$0.15 | -0.02 | $0 | |
08/12/2021 | Q3 2021 | -$0.13 | -$0.14 | -0.01 | $0 | |
05/13/2021 | Q2 2021 | -$0.12 | -$0.12 | 0 | $0 | |
02/16/2021 | Q1 2021 | -$0.12 | $0 | |||
12/28/2020 | Q4 2020 | -$0.09 | $0 | |||
08/06/2020 | Q3 2020 | -$0.14 | -$0.11 | 0.03 | $0 | |
05/07/2020 | Q2 2020 | -$0.14 | -$0.12 | 0.02 | $0 | |
02/06/2020 | Q1 2020 | -$0.12 | -$0.12 | 0 | $0 | |
12/16/2019 | Q4 2019 | -$0.15 | -$0.07 | 0.08 | $0 |
Anavex Life Sciences Corp. Earnings: Frequently Asked Questions
-
When is Anavex Life Sciences Corp.'s earnings date?
Anavex Life Sciences Corp. has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 24th, 2024 based off last year's report dates.
-
Did Anavex Life Sciences Corp. beat their earnings estimates last quarter?
In the previous quarter, Anavex Life Sciences Corp. (:AVXL) reported $-0.14 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.15 by $0.01.
-
How can I listen to Anavex Life Sciences Corp.'s earnings conference call?
The conference call for Anavex Life Sciences Corp.'s latest earnings report can be listened to online.
-
How can I read Anavex Life Sciences Corp.'s conference call transcript?
The conference call transcript for Anavex Life Sciences Corp.'s latest earnings report can be read online.
-
How much profit does Anavex Life Sciences Corp. generate each year?
Anavex Life Sciences Corp. (:AVXL) has a recorded net income of $0. Anavex Life Sciences Corp. has generated $-0.6 earnings per share over the last four quarters.
-
What is Anavex Life Sciences Corp.'s price-to-earnings ratio?
Anavex Life Sciences Corp. (:AVXL) has a price-to-earnings ratio of -16.35 and price/earnings-to-growth ratio is -0.16.